Biotech start­up grabs $27M launch round to pur­sue an R&D path blazed at Har­vard and Boston Chil­dren’s

For the past 8 years or so Bruce Bean and Clif­ford Woolf at Har­vard and Boston Chil­dren’s have been la­bor­ing in the lab to demon­strate how you could in­hib­it pain and itch sig­nal­ing in a tar­get­ed set of neu­rons. And now a VC syn­di­cate has as­sem­bled a team to take it in­to the clin­ic to see how it can per­form among hu­mans, hand­ing them a $27 mil­lion launch round.

“We run a lit­tle vir­tu­al,” No­cion Ther­a­peu­tics CEO Richard Baty­cky tells me. Right now that means 5 peo­ple on the full-time team, with plans to grow even­tu­al­ly to a lean-and-mean 15.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.